This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Foti, A. G. Articles by Cooper, J. F. Search for Related Content PubMed PubMed Citation Articles by Foti, A. G. Articles by Cooper, J. F.

A Solid-Phase Radioimmunoassay for Human Prostatic Acid Phosphatase¹

Departments of Research [A. G. F.] and Urology [J. F. C.], Southern California Permanente Medical Group, Los Angeles 90027; Kaiser Foundation Hospital, Los Angeles 90027 [J. F. C.]; and Department of Biological Chemistry and Laboratory of Nuclear Medicine, UCLA School of Medicine, Los Angeles, California 90024 [H. H.]

A solid-phase technique for radioimmunoassay of human prostatic acid phosphatase (EC 3.1.3.2) is described. Human prostatic acid phosphatase was purified from prostatic fluid. Monospecific antisera to the purified acid phosphatase were produced in rabbits. Disposable polypropylene tubes were coated with antiserum and used for radioimmunoassay with ¹²⁵I-acid phosphatase. The nonspecific binding was minimized by saturating the binding sites of the tubes with bovine serum albumin. The working range of the technique was 1 to 30 ng of antigen. The solid-phase radioimmunoassay is rapid, sensitive, and efficient. In preliminary clinical trials it was shown that (a) patients with advanced prostatic cancer had elevated prostatic acid phosphatase levels by both enzymatic assay and radioimmunoassay assays, and (b) patients with other cancers were in the normal range for prostatic acid phosphatase.

¹ This work was supported by the Southern California Permanente Medical Group (SCPMG), Los Angeles, Calif.

Received 9/ 4/74. Accepted 5/19/75.